TCT 2016: The best of the rest

The annual Transcatheter Cardiovascular Therapeutics conference went down in Washington, D.C., this week, with late-breaking study results beginning Oct. 29. After stents took center stage Day 1, with a raft of studies covering the latest on the bioresorbable front, transcatheter valve replacements were the focus on Day 2. Day 3 saw a wider variety of topics, featuring big-name devices for structural heart repair and peripheral artery disease at the Transcatheter Cardiovascular Therapies conference. Below is a roundup of miscellaneous releases from the conference: Freudenberg Medical launches new products Freudenberg Medical said it launched a trio of new technologies at TCT 2016: The FlexSeal introducer sheath, FlexSeal hemostasis valve and the Composer deflectable catheter handle platform. “These innovative devices are for companies looking to 1) accelerate time to market with a unique white-label device, 2) access new design options for improving next generation catheter and delivery systems, or 3) reduce time when building new feature sets into products,” Freudenberg said. Read more Shockwave Medical touts Disrupt CAD study, announces plans for Disrupt PAD III Shockwave Medical reported positive safety, performance and intravascular imaging data from its Disrupt CAD study and revealed its plans for the Disrupt PAD III trial, claiming it as the largest-ever multi-center randomized study of patients with calcified peripheral artery disease. Inspir...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiovascular Catheters Clinical Trials TCT 2016 Transcatheter Cardiovascular Therapeutics symposium (TCT) Source Type: news